Xtl Biopharmaceuticals LtdXTLB
Price (close)
$2.41
Market cap
$5.9M
P/E
—
Revenue (FY)
$451,000
Net income
-$1.0M
Dividend yield
—
1-year total return
-49.4%
Net margin
-227.7%
Revenue growth
—
Debt / equity
—
What Xtl Biopharmaceuticals Ltd does.
property based company, focusing on the development, management, and commercialization of intellectual property, and are engaged in
biotech through our subsidiary Psyga Bio and in the biopharmaceutical industry, in which we hold a license from Yeda Research and
that we entered into an Exclusive Sublicense Agreement with Biossil Inc., a company incorporated under the laws of Canada
Revenue and profit, by fiscal year.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $451,000 |
| Net income | $584,000 | -$3.0M | $435,000 | -$1.3M | -$1.8M | -$1.0M |
| Free cash flow | -$910,000 | -$851,000 | — | — | — | -$1.7M |
More on XTLB.
- Xtl Biopharmaceuticals Ltd summary
- Xtl Biopharmaceuticals Ltd financial statements
- Xtl Biopharmaceuticals Ltd key metrics
- Xtl Biopharmaceuticals Ltd health scores and style box
- Xtl Biopharmaceuticals Ltd earnings
- Xtl Biopharmaceuticals Ltd dividends
- Xtl Biopharmaceuticals Ltd valuation
- Xtl Biopharmaceuticals Ltd ownership and insiders
- Xtl Biopharmaceuticals Ltd peers
Figures from Xtl Biopharmaceuticals Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.